SUPERIORITY OF SIROLIMUS (RAPAMYCIN) OVER CYCLOSPORINE IN AUGMENTING ALLOGRAFT AND XENOGRAFT SURVIVAL IN MICE TREATED WITH ANTILYMPHOCYTE SERUM AND DONOR-SPECIFIC BONE MARROW1

Abstract

In the regimens tested, sirolimus was superior to cyclosporine in augmenting donor BM-induced skin graft prolongation in ALS-treated mice across all levels of histoincompatibility.